Intrarosa (Prasterone Vaginal): What People Actually Pay and Real User Reviews

What Is Intrarosa and Who Is It For?

Intrarosa is a nightly vaginal insert containing 6.5 mg of prasterone, the synthetic form of DHEA (dehydroepiandrosterone). Once placed in the vagina, prasterone is converted locally into both estrogens and androgens by enzymes in the vaginal epithelium. This local conversion restores tissue integrity without the level of systemic hormone exposure seen with oral or transdermal estrogen, though some absorption does occur.

The FDA approved Intrarosa in November 2016 specifically for moderate-to-severe dyspareunia caused by vulvovaginal atrophy, now more precisely called genitourinary syndrome of menopause (GSM). GSM affects an estimated 27 to 84 percent of postmenopausal women, yet fewer than 25 percent seek treatment, often because they assume dryness and pain are an unavoidable part of aging.

Who Specifically Benefits

Intrarosa is intended for postmenopausal women whose most bothersome GSM symptom is painful intercourse. Women who also have vaginal dryness, burning, or irritation often report improvement in those symptoms too, even though dyspareunia is the only labeled indication.

Women in perimenopause can experience GSM symptoms as estrogen fluctuates, and some clinicians prescribe prasterone off-label in this group. The evidence base here is thinner: the key trials enrolled postmenopausal women only, so perimenopause use is extrapolated, not directly studied.

Women who have had estrogen-receptor-positive breast cancer are often told to avoid systemic and even local estrogen. Because Intrarosa's primary labeling describes local conversion rather than systemic estrogen delivery, some oncologists and gynecologists consider it in this context, but the FDA label notes that systemic levels of estrogens and androgens do rise modestly. This remains a case-by-case clinical decision, not a blanket recommendation.

Who Should Not Use It

• Women who are pregnant or may become pregnant (see Pregnancy and Lactation section below)
• Women with undiagnosed abnormal uterine bleeding
• Women with known or suspected estrogen-dependent neoplasia where even local conversion is contraindicated per their oncologist

What the Clinical Trials Actually Found

The Phase 3 randomized controlled trial that supported FDA approval enrolled 557 postmenopausal women with moderate-to-severe dyspareunia as their most bothersome symptom. Participants received either prasterone 6.5 mg vaginally every night or a placebo insert for 12 weeks.

The primary endpoints were:

• Dyspareunia severity score: prasterone reduced the mean score by 1.42 points vs 0.99 points for placebo (p = 0.0002)
• Percentage of superficial cells in vaginal smear: increased significantly with prasterone vs placebo, reflecting true tissue restoration
• Vaginal pH: decreased significantly in the prasterone group, moving toward the premenopausal acidic range

Labrie et al. 2016 also found that vaginal dryness improved as a secondary endpoint, and women in the active group reported fewer days with their most bothersome symptom across the 12-week period.

What the Trial Did Not Measure Well

The trial was 12 weeks long. Women in online forums frequently ask how long they need to stay on Intrarosa, and there is limited published data on outcomes beyond three months. Long-term safety and whether women can cycle off are not well characterized in the published literature. The trial population was predominantly white and postmenopausal by natural menopause; data in surgically menopausal women or women of color is thinner.

Systemic Absorption: What It Means for You

Serum DHEA, testosterone, estradiol, and estrone all rise modestly during Intrarosa use compared to placebo. The FDA label states levels remain within postmenopausal reference ranges for most women, but values do exceed baseline. For women with hormone-sensitive conditions, this distinction matters and warrants a direct conversation with your prescriber.

What Women Actually Pay for Intrarosa

Cost is consistently the loudest complaint in every user review forum, from Reddit threads to Drugs.com ratings. Here is what the data shows.

Retail Price Without Insurance

The cash price for a 28-insert supply of Intrarosa sits between $400 and $500 at major US retail pharmacies as of early 2025. This translates to roughly $14 to $18 per insert for a drug used every night. Specialty pharmacies and mail-order pharmacy networks may offer slightly lower prices, but not dramatically so, because there is no generic prasterone vaginal insert currently on the US market.

Insurance Coverage

Commercial insurance coverage varies widely. Some plans cover Intrarosa under a Tier 3 or Tier 4 formulary position, meaning a copay of $75 to $150 per month after deductible. Other plans exclude it entirely or require step therapy through a compounded DHEA product first. Medicare Part D coverage for Intrarosa exists on select formularies, but many Part D plans do not cover it, leaving postmenopausal women on fixed incomes with the full cash price.

Manufacturer Savings Card

AMAG Pharmaceuticals (now under Millicent Pharma) has offered a savings card that can reduce out-of-pocket cost to approximately $35 to $60 per month for commercially insured patients who meet eligibility requirements. Cash-pay patients without insurance are generally not eligible for this card. Check the manufacturer's current website directly for the most up-to-date program terms, as these savings programs change.

Compounded DHEA as an Alternative

Many women who cannot afford Intrarosa ask their prescribers about compounded vaginal DHEA. Compounded preparations from 503A pharmacies may cost $60 to $120 per month. Compounded products are not FDA-approved and have not been tested in the same clinical trials, so potency, stability, and sterility vary. The ACOG Committee Opinion on compounded hormone therapy notes that compounded preparations lack the safety and efficacy data of FDA-approved products, and women should understand that trade-off before switching.

Real User Reviews: What Women on Reddit and Drugs.com Actually Say

Online reviews for Intrarosa are largely positive for symptom relief, with cost and the patience required before results appear as the two most consistent frustrations. The following synthesis draws from threads on Reddit (r/Menopause, r/Perimenopause, r/WomensHealth) and Drugs.com user reviews. These sources carry significant selection bias: women who take the time to post are often at the extremes of experience, either very satisfied or very disappointed. Sample sizes are small relative to the treated population.

The "It Takes Longer Than I Expected" Pattern

Across Reddit discussions on r/Menopause and r/Perimenopause, the most common theme is that women expected faster results and nearly stopped the medication before it started working. A representative comment type from r/Menopause reads: "I was about to give up at week four because I noticed nothing. By week six, the difference was real. Stick with it."

This aligns with the clinical trial timeline. The Labrie 2016 RCT ran for 12 weeks, and statistically significant separation from placebo was measured at the end of that period, not at week two or three. Women who judge Intrarosa at the four-week mark are evaluating an incomplete treatment course.

What Women Report Working Well

• Relief from painful intercourse, described as the primary reason they sought the drug
• Reduced vaginal burning and dryness as early as weeks three to four in some accounts
• Lack of the systemic "hormone feeling" that some women associate with oral or patch estrogen
• No messiness compared to estrogen creams (users frequently compare the suppository format favorably)

What Women Report Not Working or Disliking

• The nightly insertion routine is a barrier for some women; a subset of Drugs.com reviews mention forgetting doses or finding the applicator inconvenient
• White waxy discharge from the suppository base, noted by multiple users as unexpected but not harmful
• No effect on hot flashes or night sweats, which surprises women who hope GSM treatment will address vasomotor symptoms; Intrarosa is not indicated for and does not reliably treat vasomotor symptoms
• Cost. Repeatedly. This appears in virtually every negative or mixed review.

Drugs.com Aggregate Rating

As of early 2025, Intrarosa carries an average user rating of approximately 6.5 to 7 out of 10 on Drugs.com across several hundred reviews, placing it in the "above average" range for vaginal GSM treatments. Women rating it 8 to 10 cite dramatic pain relief; women rating it 2 to 4 cite lack of effect or inability to afford continued use.

How Intrarosa Compares to Other GSM Treatments

Women evaluating Intrarosa often ask how it fits against local vaginal estrogen (estradiol cream, Vagifem, Imvexxy), ospemifene (Osphena), and laser-based options.

| Treatment | Mechanism | Systemic Hormone Exposure | Typical Monthly Cost | |---|---|---|---| | Prasterone (Intrarosa) | Local DHEA converts to E2 and T | Low but detectable | $400-$500 cash | | Estradiol cream (generic) | Local estrogen | Very low | $30-$80 | | Estradiol tablet (Vagifem/generic) | Local estrogen | Very low | $60-$150 | | Ospemifene (Osphena) | Oral SERM, estrogen agonist in vagina | Systemic oral | $300-$400 cash | | CO2 laser (MonaLisa Touch) | Thermal tissue remodeling | None | $1,000-$1,500/session |

Generic vaginal estradiol tablets are the most cost-effective option for most postmenopausal women with GSM and no contraindication to local estrogen. The Menopause Society (formerly NAMS) 2023 position statement supports local vaginal estrogen as first-line therapy for GSM when vasomotor symptoms are not the primary complaint.

Intrarosa's specific niche is women who want to avoid even low-dose local estrogen (for personal preference or oncologic caution), women whose primary symptom is dyspareunia specifically, and women who have failed or disliked estrogen preparations.

Pregnancy, Lactation, and Contraception

Pregnancy: Contraindicated.

Intrarosa is contraindicated in pregnancy. The drug contains a steroid hormone precursor that converts to estrogens and androgens locally and partially systemically. Exogenous hormones carry theoretical risks to fetal development, and there are no adequate human pregnancy data for vaginal prasterone. The FDA label states clearly that Intrarosa should not be used in women who are pregnant.

Because Intrarosa is labeled for postmenopausal women, the practical pregnancy risk is low for most users. However, women in perimenopause who are prescribed Intrarosa off-label and who have not had twelve consecutive months without a period should confirm their contraceptive status with their prescriber before starting. Ovulation can still occur in perimenopause even with irregular cycles.

Lactation:

Intrarosa is not intended for use during lactation. DHEA and its estrogenic and androgenic metabolites may transfer into breast milk, and effects on a nursing infant are unknown. Women who are breastfeeding should not use this medication.

Contraception:

Postmenopausal women do not require contraception. Perimenopausal women using Intrarosa off-label who still have any possibility of ovulation should use effective contraception, given the theoretical fetal hormone exposure risk.

Life-Stage Breakdown: Who Is at Each Stage and What to Know

Postmenopause (Primary Indication)

This is where the evidence is strongest. If you have been postmenopausal for at least twelve months, have moderate-to-severe pain with sex, and find that vaginal dryness is diminishing your quality of life, Intrarosa is an on-label, evidence-supported choice. GSM affects an estimated 50 to 70 percent of postmenopausal women but is vastly undertreated because many women are not asked about it and do not raise it.

Perimenopause

You may experience GSM symptoms before your final menstrual period, particularly if your estrogen levels are fluctuating low. Intrarosa is not labeled for this stage. Some gynecologists prescribe it off-label, but evidence is extrapolated from postmenopausal trials. If you are perimenopausal and have bothersome dyspareunia, a conversation with your provider about labeled local estrogen options (which do have more data in perimenopause) is reasonable before moving to off-label prasterone.

Breast Cancer Survivors

GSM is extremely common in women who have completed chemotherapy, are on aromatase inhibitors, or are taking tamoxifen. Up to 90 percent of women on aromatase inhibitors report GSM symptoms. Because Intrarosa causes some systemic absorption of estradiol, its use in women with hormone-receptor-positive breast cancer must be cleared with the oncologist. No large randomized trial has specifically evaluated prasterone safety in this population. The decision involves weighing quality of life against theoretical recurrence risk.

Reproductive Years (Not Applicable)

Intrarosa is not indicated for women with regular menstrual cycles. GSM is driven by estrogen deficiency; if you are cycling normally, vulvovaginal pain has other likely causes (provoked vestibulodynia, lichen sclerosus, infections) that need separate evaluation.

How to Use Intrarosa Correctly

The standard dose is one 6.5 mg insert placed into the vagina every night at bedtime using the supplied applicator. Bedtime administration reduces the likelihood of leakage-related messiness that users mention in reviews.

Key practical points from user experience and the label:

• Consistency matters. Missing doses frequently will slow the tissue-restoration process. The nightly schedule is not optional flexibility.
• The white discharge from the suppository base is expected and not a sign of infection. Wearing a thin panty liner can help.
• Store at room temperature (below 30 degrees C). Melted inserts are ineffective and should be replaced.
• No applicator reuse if the applicator is the single-use type; check your package insert.

If you have not noticed any change by week eight, contact your prescriber. Some women need longer; others may need to confirm the diagnosis of GSM rather than assuming the drug is failing.

Who This Is Right For and Who Should Look Elsewhere

Right for You If:

• You are postmenopausal with moderate-to-severe pain during intercourse
• You have confirmed GSM on pelvic exam (vaginal pH above 5, loss of rugae, thin epithelium)
• You prefer to avoid systemic hormone therapy or local estrogen specifically
• You have insurance coverage or access to the manufacturer savings card
• You are prepared to use the insert nightly for at least 8 to 12 weeks before evaluating results

Look Elsewhere If:

• Your primary GSM symptom is vaginal dryness with no dyspareunia: a lower-cost generic vaginal estradiol tablet may work as well
• You are primarily bothered by hot flashes or night sweats: Intrarosa will not address vasomotor symptoms
• Cost is a firm barrier and compounded DHEA is not acceptable to you: generic low-dose local estrogen is substantially cheaper and well-supported by the Menopause Society
• You are pregnant, trying to conceive, or breastfeeding
• You have undiagnosed abnormal uterine bleeding that has not been evaluated

A Note on Evidence Gaps

Women have been systematically underrepresented in clinical trials for decades. For prasterone specifically, the key trial enrolled a carefully selected postmenopausal population over twelve weeks. What is not directly studied includes long-term outcomes beyond three months, use in perimenopause, safety in breast cancer survivors, pharmacokinetics in women of color (who may have different baseline DHEA levels), and outcomes when Intrarosa is combined with systemic hormone therapy. Where you read claims that go beyond these boundaries, they are extrapolated, not proven. Honest clinical practice names that gap rather than papering over it.